Find clinical trials for Acute Myeloid Leukemia (AML) in Ann Arbor, MI
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near Ann Arbor, MI, USA:
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...
Phase 3
Detroit, Michigan, United States and 125 other locations
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Detroit, Michigan, United States and 164 other locations
Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relaps...
Phase 1
Detroit, Michigan, United States and 10 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
Detroit, Michigan, United States and 78 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Ann Arbor, Michigan, United States and 43 other locations
Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML...
Phase 1
Ann Arbor, Michigan, United States and 6 other locations
inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refr...
Phase 1, Phase 2
Detroit, Michigan, United States and 34 other locations
which contains populations of CD8+ T cells targeting multiple leukemia associated antigen peptides in patients with Acute Myeloid...
Phase 1, Phase 2
Detroit, Michigan, United States and 4 other locations
). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy....
Phase 2
Detroit, Michigan, United States and 35 other locations
menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase....
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 51 other locations
Clinical trials
Research sites
Resources
Legal